Alnylam Pharma(ALNY.US)

Last Updated 19:00:00 ET
longbridge loading

Thrivent Financial for Lutherans Buys New Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
IBB
+1.75%
Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
IBB
+1.75%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Market Beat·
US
ALNY
+0.07%
US
IHE
+0.38%
US
XBI
+3.31%
Market Beat·
US
ALNY
+0.07%
US
IHE
+0.38%
US
XBI
+3.31%

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
LABU
+10.08%
Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
LABU
+10.08%

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden | ALNY Stock News

StockTitan·
US
ALNY
+0.07%
US
XLV
-0.39%
US
VHT
-0.04%
StockTitan·
US
ALNY
+0.07%
US
XLV
-0.39%
US
VHT
-0.04%

Alnylam rebuked by FDA over efficacy claims on Amvuttra website

Fiercepharma·
US
ALNY
+0.07%
US
TBXU
+0.70%
US
XLV
-0.39%
Fiercepharma·
US
ALNY
+0.07%
US
TBXU
+0.70%
US
XLV
-0.39%

Pre-market hot trades in US stocks: Alnylam Pharma up 9.59% pre-market; Biodexa Pharmaceuticals down 9.38% pre-market

Price Alert·
US
ALNY
+0.07%
US
BDRX
-0.96%
Price Alert·
US
ALNY
+0.07%
US
BDRX
-0.96%

Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
BIB
+3.26%
Market Beat·
US
ALNY
+0.07%
US
FBT
+1.45%
US
BIB
+3.26%

Alnylam Pharmaceuticals (ALNY) Valuation After Q1 2026 Profit Breakthrough And Revenue Surge

Simplywall·
US
ALNY
+0.07%
US
VHT
-0.04%
US
XBI
+3.31%
Simplywall·
US
ALNY
+0.07%
US
VHT
-0.04%
US
XBI
+3.31%

Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc

Fidelity·
US
ALNY
+0.07%
US
IBB
+1.75%
US
IHE
+0.38%
Fidelity·
US
ALNY
+0.07%
US
IBB
+1.75%
US
IHE
+0.38%

Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline

Tip Ranks·
US
ALNY
+0.07%
US
VHT
-0.04%
US
SBIO
+2.76%
Tip Ranks·
US
ALNY
+0.07%
US
VHT
-0.04%
US
SBIO
+2.76%
© 2026 Longbridge｜Disclaimer